AI assistant
HARVARD BIOSCIENCE INC — Director's Dealing 2022
May 10, 2022
34975_dirs_2022-05-10_9363aa11-030a-4793-8ba7-0a5ea8a43872.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2022-05-06
Reporting Person: Green James W (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-06 | Common Stock | P | 30000 | $3.78 | Acquired | 2309955 | Direct |
| 2022-05-09 | Common Stock | P | 10000 | $3.40 | Acquired | 2319955 | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $3.705 to $3.845, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Includes (a) 157,037 restricted stock units that will vest in three equal installments on December 29, 2022, 2023 and 2024, (b) 218,140 remaining restricted stock units that will vest on June 11, 2022 and 2023, (c) 129,799 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (d) 109,070 remaining restricted stock units that will vest on December 29, 2022 and 2023, (e) 104,590 remaining restricted stock units that will vest on January 1, 2023, (f) 541,218 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (g) 1,050,101 shares of common stock beneficially owned by the Reporting Person.
F3: This transaction was executed in multiple trades at prices ranging from $3.375 to $3.41, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: Includes (a) the shares and awards described in footnote (2) above, and (b) the shares purchased in the transaction described in footnote (3) above.